Everlab Is Building an AI-Powered Healthcare Platform for Predictive, Preventive Care
Everlab’s Vision for Predictive Healthcare
Modern healthcare is remarkably effective at treating disease, but much of the system is still built around responding when something goes wrong. Everlab wants to move that equation forward by making prevention more proactive, data-driven, and continuous. The Australian healthtech company is building a healthcare platform that brings diagnostics, clinicians, specialists, prescriptions, and AI-powered care into a single experience. Its process begins by creating a health baseline, including gathering historical medical records and analysing existing health information. An Everlab doctor then reviews the patient’s history, risks, and goals before creating a personalised diagnostic plan.
The platform can subsequently track results over time, allowing clinicians and patients to identify trends rather than looking at individual test results in isolation. Everlab’s approach is particularly focused on detecting potential risks before symptoms emerge. Its platform uses AI-powered analysis to identify areas of risk and opportunity, while medical professionals remain involved in interpreting results and developing personalised action plans.
The company says its goal is to help people detect, prevent, and potentially reverse disease risk years before conventional symptoms appear. This represents a broader shift from episodic healthcare toward longitudinal health management, where a person’s health history, biomarkers, imaging, genetics, lifestyle, and progress are considered together. Everlab’s ambition is effectively to create a continuous feedback loop between diagnostics, medical expertise, intervention, and monitoring.
Inside Everlab’s Testing: From ApoB and Lp(a) to MRI and Genetic Screening
Everlab’s diagnostic platform is built around the idea that no single test can provide a complete picture of someone’s future health. Instead, the company offers a broad toolkit covering cardiovascular, metabolic, hormonal, genetic, physical, and other areas, with doctors selecting tests according to an individual’s history, risk profile, and goals. Its advanced blood testing includes biomarkers associated with cardiovascular and metabolic health, while cardiovascular assessments can include ApoB, Lp(a), coronary calcium scoring, and CT coronary angiography.
Genetic testing includes assessments such as ApoE and broader panels examining inherited risks, while other offerings include DNA methylation analysis and pharmacogenetics. Everlab also provides DEXA scans for body composition and bone density, VO₂ max and physical assessments, gut microbiome testing, and imaging options including full-body MRI combined with ultra-low-dose chest CT. The company’s full-body imaging programme is designed to provide a more comprehensive view of anatomical health, with scans reviewed by radiologists and interpreted by Everlab doctors.
What makes the platform different from a collection of premium diagnostic tests is the way Everlab attempts to connect these results. Its doctors use the patient’s history and diagnostic findings to identify priorities and create an action plan covering areas such as exercise, nutrition, sleep, recovery, supplementation, and medical intervention where appropriate. Results can then be tracked through the Everlab app, with repeat testing used to measure changes and refine the plan. The company’s proposition is therefore not simply “more testing.” It is the creation of a longitudinal health profile in which different pieces of information can be interpreted together and revisited over time.
Everlab Raises A$65 Million to Scale Its Preventive Healthcare Platform
Everlab’s vision has attracted significant investor support as interest in preventive and longevity-focused healthcare continues to grow. In June 2026, the Melbourne-based company raised A$65 million in Series A funding, in an oversubscribed round led by Airtree Ventures, with participation from Plural, existing investors Left Lane Capital and b2venture, and angel investor Pat Cummins. The funding marks an important stage in Everlab’s evolution from a preventative health service into a broader healthcare platform.
The company says its digital app brings together diagnostics, doctors, specialists, prescriptions, and continuous AI care, giving patients a longitudinal view of their health rather than forcing them to manage information across disconnected providers. That ambition addresses a fundamental weakness in traditional healthcare: medical information is often fragmented across clinics, laboratories, imaging providers, specialists, and personal health applications.
Everlab wants to create a single layer through which that information can be organised, interpreted, and acted upon. The Series A provides capital to expand that platform and make its preventative healthcare model available to a much larger audience. The challenge is significant because healthcare is highly regulated, clinically complex, and dependent on patient trust. Everlab must demonstrate that combining extensive diagnostics with AI-powered analysis and clinician oversight can produce meaningful outcomes rather than simply generating more health data. If it succeeds, however, the model could shift preventative healthcare from an occasional check-up into an ongoing service that continuously measures risk and helps people act before disease becomes symptomatic.
Can Everlab Make Preventive Healthcare the New Normal?
The biggest question for Everlab is whether preventative healthcare can move from a premium service for highly health-conscious consumers into a mainstream part of how people manage their health. The technology is increasingly available to make that possible. Advanced blood testing, genetic analysis, medical imaging, wearable data, AI, and digital health records can collectively provide a far more detailed picture of an individual’s health than was possible in previous generations. But more information does not automatically translate into better healthcare. Patients need qualified clinicians to interpret results, distinguish meaningful risks from noise, and determine which interventions are actually appropriate.
Everlab’s model attempts to address this by placing doctors at the centre of the diagnostic and action-planning process while using AI and software to organise information, identify trends, and support continuous monitoring. Its workplace and executive health offerings also create a potential path beyond individual consumers, allowing employers to incorporate preventative health into their benefits and workforce strategies. The larger opportunity is to change when healthcare begins.
Instead of waiting for a person to develop symptoms and then treating the resulting condition, preventative platforms like Everlab are betting that healthcare can identify risks earlier and intervene while there is still time to change the trajectory. That does not mean every disease can be prevented, nor that extensive screening is appropriate for everyone. It does suggest that a more personalised, data-rich approach could complement conventional primary care. Everlab now has the funding and infrastructure to test whether that proposition can scale. If it can demonstrate that early detection, personalised intervention, and continuous monitoring produce better long-term outcomes, it could help make preventative healthcare a more normal part of modern medicine.